Tamtam Try Tamtam free
Evolent logo

Evolent account plan

specialty-focused value-based care

At a glance

Evolent manages oncology, cardiology and musculoskeletal care for US health plans: $1,876.2 million FY2025 revenue, about 4,200 employees.

Evolent (NYSE: EVH), headquartered in Arlington, Virginia, manages specialty care for people with complex conditions, chiefly cancer, cardiovascular disease and musculoskeletal diagnoses, on behalf of health plans and other risk-bearing payers; all revenue is recognized in the United States. It works through specialist networks, evidence-based clinical pathways and its own technology (the CarePro workflow platform and the Identifi platform). FY2025 revenue fell 26.6% to $1,876.2 million, and the net loss attributable to common shareholders was $579.4 million, driven by a $398.0 million non-cash goodwill impairment. It had about 4,200 employees as of February 16, 2026, with offices in the US, Pune (India) and Manila (Philippines). Founded in 2011, it listed on the NYSE in June 2015.

Business units

Strategic priorities

Oncology as the core business
CEO Seth Blackley expects oncology to represent over 70% of Evolent's 2027 revenue. Evolent is embedding clinical pathways directly into the EMRs of leading oncology groups and expanding Member Navigation.
AI-driven prior-authorization review
AuthIntelligence, built from the 2024 Machinify acquisition, evaluates about half of the prior-authorization volume that needed manual review, about 1 million cases a year. The target is more than 80% of manual auths, about 2 million cases, by end 2027; company policy forbids using AI to deny care.
Renewals and expansions with existing payers
Seven new revenue agreements and renewals were signed year to date by Q3 2026, including a national payer adding 11 states to an existing 39 in oncology and an existing client expanding oncology to about 1 million Commercial lives from January 1, 2027.
Margin and cash over revenue growth
CFO Mario Ramos says Evolent is prioritizing margin and cash generation over revenue growth, with a 2027 Adjusted EBITDA midpoint expected at $150 million or higher, helped by Performance Suite margin maturation and an enterprise-wide cost review.
Fixing the capital structure
Evolent plans to deploy up to $50 million to reduce debt by year end 2026 and is evaluating capital markets and strategic alternatives to improve leverage and its 2029 maturities within 12 to 24 months.

Latest results

In Q3 2026 (three months to September 30, 2026) revenue rose 51.3% year on year to $725.4 million, mainly from $280.1 million of new Performance Suite go-lives and expanded oncology services for an existing customer. Net loss attributable to common shareholders narrowed to $23.6 million from $26.9 million, while Adjusted EBITDA fell to $34.3 million (4.7% margin, down from 8.1%) as low-margin capitated revenue grew. The Medical Expense Ratio was 93.0% (Q3 2025: 85.0%), and SG&A fell 5.8% to $73.1 million. Nine-month revenue was $1,874.1 million, up 33.2%. Full-year 2026 guidance is revenue of $2.6 billion to $2.7 billion (reiterated) and Adjusted EBITDA of $130.0 million to $135.0 million (raised), with capital expenditure of $26 million to $28 million.

Investments and deals

Sale of Evolent Care Partners
The ACO / total cost of care business was sold for $100.0 million plus up to $13.0 million contingent, closing December 5, 2025; cash proceeds were $91.3 million and $82.8 million of term loan was repaid.
2025 refinancing
$166.8 million of 2031 convertible notes were issued in August 2025, the 2025 notes retired, $40.0 million of shares repurchased, and the Series A Preferred Stock exchanged for a $175.0 million second-lien term loan with Ares.
Machinify and AuthIntelligence
The 2024 Machinify acquisition underpins AuthIntelligence; AI-related capex is expected to be higher in 2027 than 2026, with returns from late 2027.
Capital expenditure
$34.1 million of internal-use software and equipment in 2025; capitalized expenditures of $26 million to $28 million guided for 2026.
New oncology Performance Suite partnership
An existing advanced imaging client signed an oncology Performance Suite partnership covering about 1.5 million Medicaid and Medicare lives in 11 states, with launch expected by December 2026 and about $300 million of annualized revenue.

Challenges and risks

Customer concentration
In Q3 2026 Highmark was 28.1% of revenue, Molina 23.1%, Aetna 12.8% and Cook County Health 11.4%; many specialty contracts are terminable without cause after an initial term on 30 to 180 days' notice.
Medicaid and exchange membership pressure
The One Big Beautiful Bill Act's Medicaid and ACA changes are expected to bring higher acuity and lower membership; customers reported Medicaid and Health Exchange membership declines in Q3 2026.
Rising specialty medical costs under risk contracts
Medical claims costs grew faster than historical norms in 2024 and 2025, and Evolent anticipates continued growth in the cost of cancer and cardiovascular treatment, exposing its capitated Performance Suite contracts.
Leverage
Net debt was $776 million at Q3 2026, with a $117.2 million term loan, $62.5 million revolver, $175.0 million second-lien loan and $569.25 million of convertible note principal outstanding.
Scrutiny of prior authorization and AI
Federal and state scrutiny of prior authorization is rising (CMS-4201-F, state gold carding laws, CMS-0057-F timeframes from January 1, 2026), and at least 40 states introduced or enacted AI legislation in 2024.

What leadership says

“I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come.”

Seth Blackley, Co-Founder and Chief Executive Officer · Evolent Announces Third Quarter 2026 Results, press release, 2026-11-05

“In our core offering, we do not feel like we have direct competitors that can do what we do and the way we do it.”

Seth Blackley, Co-Founder and Chief Executive Officer · Q3 2026 earnings call, 2026-11-05

“we are prioritizing margin and cash generation over revenue growth”

Mario Ramos, Chief Financial Officer · Q3 2026 earnings call, 2026-11-05

“There's 140+ million auths a year that happen in the U.S. We're doing 9 million of them”

Seth Blackley, Co-Founder and Chief Executive Officer · Q3 2026 earnings call, 2026-11-05

Where a supplier can help

AI and clinical data tooling
The AuthIntelligence target of more than 80% of manual auths by end 2027, and higher AI capex in 2027, create room for suppliers of AI infrastructure, clinical data extraction and model governance that respects the no-AI-denial policy.
Cost reduction and operations efficiency
The enterprise-wide cost review and the priority on margin and cash point to vendors who lower operating cost in review, call center and offshore operations in Pune and Manila.
EMR integration for oncology pathways
Embedding clinical pathways into oncology groups' EMRs and expanding Member Navigation calls for interoperability, integration and patient-engagement capabilities.
Regulatory compliance for prior authorization
CMS-0057-F decision timeframes and interface requirements, plus state AI legislation, open a need for compliance, interface and audit tooling around utilization management.
Launch support for new Performance Suite contracts
The oncology partnership launching by December 2026 and the January 1, 2027 oncology expansion require provider network, implementation and claims analytics capacity.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Evolent?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Evolent

What does Evolent do?

Evolent manages specialty care for people with complex conditions, chiefly cancer, cardiovascular disease and musculoskeletal diagnoses, on behalf of US health plans and other risk-bearing payers. It combines specialist networks, clinical pathways and proprietary technology, and takes on claims risk in its capitated Performance Suite.

What is Evolent's revenue?

FY2025 revenue was $1,876.2 million, down 26.6%. Q3 2026 revenue was $725.4 million, and 2026 revenue guidance is $2.6 billion to $2.7 billion.

How many employees does Evolent have?

About 4,200 employees as of February 16, 2026, with offices in the US, Pune (India) and Manila (Philippines).

Who leads Evolent?

Seth Blackley, co-founder, has been CEO since October 2020; Dan McCarthy is President and Mario Ramos has been CFO since January 2026.

What is Evolent's strategy?

Evolent is centering on oncology, expected to be over 70% of 2027 revenue, and on AI for prior-authorization review through AuthIntelligence, while prioritizing margin and cash generation and reducing debt.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)